{
  "docId": "019de076-906b-74a9-92f8-5c2872231d60",
  "docSlug": "a8776e7183e96a109d1a49143fc2ff88",
  "documentTitle": "Arbutus Biopharma | Investor Presentation Deck | 26 slides",
  "authorId": "arbutus-biopharma",
  "authorName": "Arbutus Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 16,
  "pageCount": 26,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "appendix_methodology",
  "function": "plan_implementation",
  "density": "overcrowded",
  "nDataPoints": 6,
  "notes": "Shows two parallel study arms with randomization at week 24/26.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-906b-74a9-92f8-5c2872231d60/16",
  "deckHref": "/decks/019de076-906b-74a9-92f8-5c2872231d60",
  "deckJsonHref": "/decks/019de076-906b-74a9-92f8-5c2872231d60.json",
  "deckAnchorHref": "/decks/019de076-906b-74a9-92f8-5c2872231d60#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.65,
        "x": 0.32,
        "y": 0.15
      },
      "kind": "diagram",
      "text": "Clinical trial study design timeline",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b482aff1-c2d7-44d1-93ac-f2cd33c61c42",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.15,
        "x": 0.05,
        "y": 0.91
      },
      "kind": "image",
      "text": "Arbutus Biopharma logo",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7219b94e-36b5-4ec2-82af-ae61e559f005",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.2,
        "x": 0.05,
        "y": 0.41
      },
      "kind": "image",
      "text": "Barinthus Biotherapeutics logo",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9278ad35-bc15-49be-b051-8239cb74c8d4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.65,
        "x": 0.32,
        "y": 0.6
      },
      "kind": "paragraph",
      "text": "Primary objective: evaluate safety and reactogenicity of imdusiran followed by VTP-300 or placebo. At Week 48 all participants who are eligible to discontinue NA therapy will be followed for an additional 48 weeks. Preliminary results presented at AASLD The Liver Meeting 2023. Clinical trial expanded to include an additional arm with nivolumab (Opdivo®) with preliminary data expected in 2H 2024. Full rights retained by the Companies of their respective product candidates and all costs split equally",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3cfe5655-f833-4617-9507-7f2976683ea3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.25,
        "x": 0.04,
        "y": 0.53
      },
      "kind": "paragraph",
      "text": "POC Phase 2a clinical trial evaluating imdusiran in combination with Barinthus Bio’s immunotherapeutic, VTP-300, NA and with or without low dose nivolumab. End-of-treatment data for Imdusiran + VTP-300 + NA expected in 1H 2024",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ee44409e-60ef-4985-ba9d-bb01dc154c13",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.25,
        "x": 0.04,
        "y": 0.21
      },
      "kind": "title",
      "text": "AB-729-202: Phase 2a POC Clinical Trial",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d5b8c166-9a44-4aa8-b5cf-d6ea3300fbe3",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "gantt-chart",
      "slug": null,
      "matchId": "ba0b088e-f94c-4298-9232-1cbb1bef884f",
      "evidence": "Timeline visualization of clinical trial phases",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 26,
      "from": 8,
      "beatId": "b0891741-a256-4e4e-a8d2-65a9f9895b7f",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The document presents Arbutus Biopharma's pipeline and clinical trial results as a solution.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    },
    {
      "to": 18,
      "from": 11,
      "beatId": "bb704643-20a7-459a-9df1-5b5cea9225d9",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "The document presents clinical trial results and data.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 18,
      "from": 11,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "9268b1b4-494b-44ee-8454-6a997fc0aa8b",
      "evidence": "The document presents clinical trial results and data.",
      "position": 1,
      "objective": "Can Imdusiran RNAi therapeutic and AB-101 oral PD-L1 inhibitor provide a quick win or a big bet for investors?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}